Valiant Organics (VALIANTORG) 주식 개요화학물질 제조 회사인 Valiant Organics Limited는 인도에서 특수 화학물질을 제조 및 판매하는 회사입니다. 자세히 보기VALIANTORG 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적2/6재무 건전성5/6배당0/6강점올해부터 흑자전환위험 분석지난 5년간 매년 수익이 46.1% 감소했습니다.지난 3개월 동안 주가 변동성이 Indian 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다(₹8B)모든 위험 점검 보기VALIANTORG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹279.90186.5% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-84m12b2016201920222025202620282031Revenue ₹4.8bEarnings ₹214.5mAdvancedSet Fair ValueView all narrativesValiant Organics Limited 경쟁사Tamilnadu PetroproductsSymbol: BSE:500777Market cap: ₹7.7bPetro Carbon and ChemicalsSymbol: NSEI:PCCLMarket cap: ₹6.8bTuticorin Alkali Chemicals and FertilizersSymbol: BSE:506808Market cap: ₹6.6bAgarwal IndustrialSymbol: BSE:531921Market cap: ₹7.2b가격 이력 및 성과Valiant Organics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹279.9052주 최고가₹507.8052주 최저가₹195.00베타0.491개월 변동-5.96%3개월 변동29.84%1년 변동-39.24%3년 변동-50.16%5년 변동-82.26%IPO 이후 변동-81.01%최근 뉴스 및 업데이트분석 기사 • May 24Valiant Organics' (NSE:VALIANTORG) Solid Profits Have Weak FundamentalsValiant Organics Limited's ( NSE:VALIANTORG ) stock was strong after they recently reported robust earnings. We did...공시 • May 20Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP.Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP on May 19, 2026. A cash consideration will be paid by Valiant Organics Limited. As part of consideration, Valiant Organics Limited declared that the acquisition price would not be higher by more than 25% of the price computed of INR 62.71 per equity share, based on the volume weighted average market price for a period of 60 trading days. The proposed acquisition is part of the restructuring exercise being undertaken by Valiant Organics Limited. Upon completion, Dhanvallabh Ventures LLP will retain 12.58% stake in Valiant Laboratories Limited. Subject to receipt of requisite approvals, the acquisition will be done any time after 4 working days from the date of this intimation.Reported Earnings • May 17Full year 2026 earnings released: EPS: ₹11.86 (vs ₹1.35 loss in FY 2025)Full year 2026 results: EPS: ₹11.86 (up from ₹1.35 loss in FY 2025). Revenue: ₹7.46b (up 3.7% from FY 2025). Net income: ₹332.4m (up ₹369.7m from FY 2025). Profit margin: 4.5% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.공시 • May 12Valiant Organics Limited to Report Q4, 2026 Results on May 16, 2026Valiant Organics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 16, 2026Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹306, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 35% over the past three years.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹239, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 46% over the past three years.더 많은 업데이트 보기Recent updates분석 기사 • May 24Valiant Organics' (NSE:VALIANTORG) Solid Profits Have Weak FundamentalsValiant Organics Limited's ( NSE:VALIANTORG ) stock was strong after they recently reported robust earnings. We did...공시 • May 20Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP.Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP on May 19, 2026. A cash consideration will be paid by Valiant Organics Limited. As part of consideration, Valiant Organics Limited declared that the acquisition price would not be higher by more than 25% of the price computed of INR 62.71 per equity share, based on the volume weighted average market price for a period of 60 trading days. The proposed acquisition is part of the restructuring exercise being undertaken by Valiant Organics Limited. Upon completion, Dhanvallabh Ventures LLP will retain 12.58% stake in Valiant Laboratories Limited. Subject to receipt of requisite approvals, the acquisition will be done any time after 4 working days from the date of this intimation.Reported Earnings • May 17Full year 2026 earnings released: EPS: ₹11.86 (vs ₹1.35 loss in FY 2025)Full year 2026 results: EPS: ₹11.86 (up from ₹1.35 loss in FY 2025). Revenue: ₹7.46b (up 3.7% from FY 2025). Net income: ₹332.4m (up ₹369.7m from FY 2025). Profit margin: 4.5% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.공시 • May 12Valiant Organics Limited to Report Q4, 2026 Results on May 16, 2026Valiant Organics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 16, 2026Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹306, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 35% over the past three years.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹239, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 46% over the past three years.Valuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹259, the stock trades at a trailing P/E ratio of 33.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 46% over the past three years.New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₹6.66b market cap, or US$71.8m).Reported Earnings • Feb 15Third quarter 2026 earnings released: EPS: ₹1.30 (vs ₹1.08 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.30. Revenue: ₹1.61b (down 14% from 3Q 2025). Net income: ₹36.5m (down 33% from 3Q 2025). Profit margin: 2.3% (down from 2.9% in 3Q 2025).Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹280, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 35% over the past three years.공시 • Feb 09Valiant Organics Limited to Report Q3, 2026 Results on Feb 13, 2026Valiant Organics Limited announced that they will report Q3, 2026 results on Feb 13, 2026분석 기사 • Feb 06Is Valiant Organics (NSE:VALIANTORG) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Nov 25Getting In Cheap On Valiant Organics Limited (NSE:VALIANTORG) Is UnlikelyThere wouldn't be many who think Valiant Organics Limited's ( NSE:VALIANTORG ) price-to-sales (or "P/S") ratio of 1x is...Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹2.02 (vs ₹4.52 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.02 (up from ₹4.52 loss in 2Q 2025). Revenue: ₹1.58b (down 1.7% from 2Q 2025). Net income: ₹56.7m (up ₹184.5m from 2Q 2025). Profit margin: 3.6% (up from net loss in 2Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.공시 • Nov 10Valiant Organics Limited to Report Q2, 2026 Results on Nov 13, 2025Valiant Organics Limited announced that they will report Q2, 2026 results on Nov 13, 2025New Risk • Oct 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.84b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.84b market cap, or US$99.6m).공시 • Sep 01Valiant Organics Limited, Annual General Meeting, Sep 26, 2025Valiant Organics Limited, Annual General Meeting, Sep 26, 2025, at 11:30 Indian Standard Time.Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹2.93 (vs ₹0.23 loss in 1Q 2025)First quarter 2026 results: EPS: ₹2.93 (up from ₹0.23 loss in 1Q 2025). Revenue: ₹2.05b (up 22% from 1Q 2025). Net income: ₹82.0m (up ₹88.2m from 1Q 2025). Profit margin: 4.0% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.공시 • Aug 09Valiant Organics Limited to Report Q1, 2026 Results on Aug 13, 2025Valiant Organics Limited announced that they will report Q1, 2026 results on Aug 13, 2025분석 기사 • Jul 30Be Wary Of Valiant Organics (NSE:VALIANTORG) And Its Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...분석 기사 • May 30Is Valiant Organics (NSE:VALIANTORG) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 23Full year 2025 earnings released: ₹1.24 loss per share (vs ₹3.08 loss in FY 2024)Full year 2025 results: ₹1.24 loss per share (improved from ₹3.08 loss in FY 2024). Revenue: ₹7.27b (flat on FY 2024). Net loss: ₹37.4m (loss narrowed 56% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.공시 • May 19Valiant Organics Limited to Report Q4, 2025 Results on May 22, 2025Valiant Organics Limited announced that they will report Q4, 2025 results on May 22, 2025New Risk • May 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.33b (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.33b market cap, or US$97.3m).분석 기사 • Apr 21Subdued Growth No Barrier To Valiant Organics Limited (NSE:VALIANTORG) With Shares Advancing 25%Valiant Organics Limited ( NSE:VALIANTORG ) shareholders would be excited to see that the share price has had a great...Board Change • Apr 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Non-Executive Independent Director Sudhir Prakash Sawant was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공시 • Feb 07Valiant Organics Limited to Report Q3, 2025 Results on Feb 13, 2025Valiant Organics Limited announced that they will report Q3, 2025 results at 3:30 PM, Indian Standard Time on Feb 13, 2025공시 • Jan 03+ 1 more updateValiant Organics Limited Approves the Appointment of Parimal H Desai as Managing DirectorValiant Organics Limited announced that Shri. Parimal H Desai appointed as Non- Executive Director effective from May 24, 2024 and subsequently as an Executive Director and Managing Director effective from January 01, 2025 as per the terms and conditions mentioned in the resolution approved by the shareholders through remote e-voting system. Reason for Change: Designated as Managing Director pursuant to section 196, 197, 203 read with Schedule V of the Companies Act, 2013. Shri. Parimal Desai holds a bachelor's degree in Chemical Engineering from UDCT, Mumbai. He is a proven technocrate with rich experience of nearly five decades in Chemical Industry, including Product Development, Project.New Risk • Dec 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.40b (US$98.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 32% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.40b market cap, or US$98.2m).Reported Earnings • Nov 15Second quarter 2025 earnings released: ₹4.52 loss per share (vs ₹1.58 profit in 2Q 2024)Second quarter 2025 results: ₹4.52 loss per share (down from ₹1.58 profit in 2Q 2024). Revenue: ₹1.63b (down 20% from 2Q 2024). Net loss: ₹127.8m (down 397% from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance.공시 • Nov 09Valiant Organics Limited to Report Q2, 2025 Results on Nov 13, 2024Valiant Organics Limited announced that they will report Q2, 2025 results on Nov 13, 2024공시 • Aug 07Valiant Organics Limited to Report Q1, 2025 Results on Aug 13, 2024Valiant Organics Limited announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • Aug 01Full year 2024 earnings released: ₹3.08 loss per share (vs ₹32.45 profit in FY 2023)Full year 2024 results: ₹3.08 loss per share (down from ₹32.45 profit in FY 2023). Revenue: ₹7.23b (down 31% from FY 2023). Net loss: ₹83.9m (down 110% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 33% per year.공시 • Jul 25Valiant Organics Limited, Annual General Meeting, Aug 21, 2024Valiant Organics Limited, Annual General Meeting, Aug 21, 2024, at 11:30 Indian Standard Time.Reported Earnings • May 27Full year 2024 earnings released: ₹3.07 loss per share (vs ₹32.45 profit in FY 2023)Full year 2024 results: ₹3.07 loss per share (down from ₹32.45 profit in FY 2023). Revenue: ₹7.32b (down 30% from FY 2023). Net loss: ₹83.9m (down 110% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 36% per year.공시 • May 25Valiant Organics Limited Announces Board Changes and Reconstitution of Committees of the BoardThe board of directors of Valiant Organics Limited at its meeting held on May 24, 2024, Appointment of Mr. Kaustubh Kulkarni (ACS: 52980) as the Company Secretary, Key Managerial Personnel and Compliance Officer of the Company with effect from May 24, 2024. Mr. Vishnu Sawant (DIN: 03477593) has tendered his resignation as an Executive Director of the Company with effect from close of business hours of May 31, 2024 citing pre-occupation and other personal commitments. Mr. Kaustubh Kulkarni (ACS 52980), is a member of the Institute of Company Secretaries of India and L.L.B. Graduate from Mumbai University. Mr. Kaustubh has over 7+ years of experience in dealing with Secretarial Compliances of Listed and Unlisted Companies across organizations engaged in the Pharmaceutical, Information Technology and Financial sector. Reconstitution of Committees of the Board: Corporate Social Responsibility Committee: Mr. Navin C. Shah: Independent Director, Chairperson; Mr. Mahek M. Chheda:Executive Director, Member; Mr. Nemin M. Savadia: Executive Director, Member. Risk Management Committee: Mr. Parimal H. Desai: Additional Non-Executive Director (Vice Chairman - Designated), Chairperson; Mr. Mulesh M. Savla: Independent Director, Member; Mr. Mahek M. Chheda: Executive Director, Member; Mr. Kallada K. Sathiababu: Executive Director, Member. Stakeholders Relationship Committee: Mr. Mulesh M. Savla: Independent Director, Chairperson; Mr. Navin C. Shah: Independent Director, Member; Mr. Mahek M. Chheda: Executive Director, Member.Board Change • May 24Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Non-Executive Independent Director Sudhir Prakash Sawant was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공시 • May 18Valiant Organics Limited to Report Q4, 2024 Results on May 24, 2024Valiant Organics Limited announced that they will report Q4, 2024 results on May 24, 2024New Risk • Feb 15New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 7.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin).Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹2.90 loss per share (vs ₹8.09 profit in 3Q 2023)Third quarter 2024 results: ₹2.90 loss per share (down from ₹8.09 profit in 3Q 2023). Revenue: ₹1.42b (down 43% from 3Q 2023). Net loss: ₹78.9m (down 136% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.공시 • Feb 06Valiant Organics Limited to Report Q3, 2024 Results on Feb 13, 2024Valiant Organics Limited announced that they will report Q3, 2024 results on Feb 13, 2024New Risk • Nov 13New major risk - Revenue and earnings growthEarnings have declined by 5.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹1.53 (vs ₹7.72 in 2Q 2023)Second quarter 2024 results: EPS: ₹1.53 (down from ₹7.72 in 2Q 2023). Revenue: ₹2.07b (down 22% from 2Q 2023). Net income: ₹43.0m (down 80% from 2Q 2023). Profit margin: 2.1% (down from 7.9% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.New Risk • Nov 09New major risk - Revenue and earnings growthEarnings have declined by 3.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.분석 기사 • Aug 31Estimating The Fair Value Of Valiant Organics Limited (NSE:VALIANTORG)Key Insights Valiant Organics' estimated fair value is ₹424 based on 2 Stage Free Cash Flow to Equity With ₹506 share...공시 • Aug 24Valiant Organics Limited, Annual General Meeting, Sep 15, 2023Valiant Organics Limited, Annual General Meeting, Sep 15, 2023, at 11:00 Indian Standard Time. Agenda: To consider and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2023 together with the Reports of the Board of Directors' and the Auditors' thereon; to appoint a Director in place of Dr. Kiritkumar H. Desai; to appoint a Director in place of Shri Sathiababu K. Kallada; to discuss re-appoint the Statutory Auditors of the Company; to approve revision in terms & conditions of appointment of Shri Arvind K. Chheda Managing Director of the Company; and to discuss other matters.Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: ₹4.58 (vs ₹5.68 in 1Q 2023)First quarter 2024 results: EPS: ₹4.58 (down from ₹5.68 in 1Q 2023). Revenue: ₹2.05b (down 23% from 1Q 2023). Net income: ₹124.2m (down 20% from 1Q 2023). Profit margin: 6.1% (up from 5.8% in 1Q 2023). The increase in margin was driven by lower expenses.공시 • Aug 03Valiant Organics Limited to Report Q1, 2024 Results on Aug 09, 2023Valiant Organics Limited announced that they will report Q1, 2024 results on Aug 09, 2023공시 • Jul 06Valiant Organics Limited Announces Cessation of Shri Velji Karamshi Gogri as an Independent Director Effective July 05, 2023Valiant Organics Limited announced that Shri Velji Karamshi Gogri (DIN: 02714758) completed his second consecutive term as an Independent Director on July 05, 2023 and consequently cease to be a Director of the Company with effect from closing of Business hours on July 05, 2023. The Board of Directors places on record appreciation for his contribution as an Independent Director with the Company.Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹582, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 15% over the past year.분석 기사 • May 24Valiant Organics (NSE:VALIANTORG) Will Be Hoping To Turn Its Returns On Capital AroundFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...공시 • May 21Valiant Organics Limited Announces Change in DirectorateValiant Organics Limited announced that Board of Directors at its Meeting held on May 19, 2023, have approved the appointment of Dr. Sudhirprakash B. Sawant (DIN: 02343218) as Additional Director in the Category of Non-Executive Independent Director the Company for a term of 5 (five) Years with effect from May 19, 2023 based on recommendation of Nomination and Remuneration Committee and subject to the approval of Members. Dr. Sudhirprakash B. Sawant holds a Bachelor's degree in Chemical Engineering and PhD. (Tech). He was a faculty member in Chemical Engineering. He has served as a consultant to various Chemical companies for more than 30 years. He has also served as an expert member on various committees of Central & State Governments.Reported Earnings • May 21Full year 2023 earnings released: EPS: ₹32.45 (vs ₹41.72 in FY 2022)Full year 2023 results: EPS: ₹32.45 (down from ₹41.72 in FY 2022). Revenue: ₹10.6b (down 8.1% from FY 2022). Net income: ₹881.2m (down 22% from FY 2022). Profit margin: 8.3% (down from 9.8% in FY 2022). The decrease in margin was driven by lower revenue.공시 • May 20Valiant Organics Limited Announces Reconstitution of Committees of the BoardValiant Organics Limited announced that at its board meeting held on May 19, 2023, approved reconstitution of Committees of the Board. Audit Committee: Shri Mulesh Savla - Independent Director, Chairman, Shri Arvind Chheda - Managing Director, Member, Shri Navin Shah - Independent Director, Member, Shri Sathiababu Kallada - Executive Director, Member, Smt. Sonal Vira - Independent Director, Member, Dr. Sudhirprakash B. Sawant - Independent Director, Member; Nomination and Remuneration Committee: Shri Mulesh Savla - Independent Director, Chairperson, Shri Santosh Shantilal Vora - Non-Executive Director, Member, Shri Navin Shah - Independent Director, Member; Risk Management Committee: Shri Mulesh Savla - Independent Director, Chairperson, Shri Mahek Manoj Chheda - Executive Director, Member, Shri Arvind Kanji Chheda - Managing Director, Member; Corporate Social Responsibility Committee: Shri Navin Shah - Independent Director, Chairperson, Shri Mahek Manoj Chheda - Executive Director, Member, Shri Arvind Kanji Chheda - Managing Director, Member.공시 • May 13Valiant Organics Limited to Report Q4, 2023 Results on May 19, 2023Valiant Organics Limited announced that they will report Q4, 2023 results on May 19, 2023Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹505, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 46% over the past year.Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹477, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 19x in the Chemicals industry in India. Total loss to shareholders of 52% over the past year.Upcoming Dividend • Feb 03Upcoming dividend of ₹1.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 10 February 2023. Payment date: 02 March 2023. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).공시 • Feb 01Valiant Organics Limited Declares Interim Dividend for the Financial Year 2022-2023Valiant Organics Limited announced that the board of directors of the company at its meeting held on January 31, 2023 has declared the interim dividend of INR 1 (10%) per equity share of INR 10 each for the financial year 2022-2023. Pursuant to Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, the board has fixed February 10, 2023, as record date for the purpose of payment of interim dividend.Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹8.09 (vs ₹11.02 in 3Q 2022)Third quarter 2023 results: EPS: ₹8.09 (down from ₹11.02 in 3Q 2022). Revenue: ₹2.52b (down 13% from 3Q 2022). Net income: ₹219.7m (down 27% from 3Q 2022). Profit margin: 8.7% (down from 10% in 3Q 2022). The decrease in margin was driven by lower revenue.공시 • Jan 24Valiant Organics Limited to Report Q3, 2023 Results on Jan 31, 2023Valiant Organics Limited announced that they will report Q3, 2023 results on Jan 31, 2023Recent Insider Transactions • Dec 19Insider recently sold ₹2.9m worth of stockOn the 15th of December, Indira Dedhia sold around 5k shares on-market at roughly ₹637 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.9m. Insiders have been net sellers, collectively disposing of ₹119m more than they bought in the last 12 months.Price Target Changed • Nov 16Price target decreased to ₹1,382Down from ₹1,980, the current price target is provided by 1 analyst. New target price is 110% above last closing price of ₹657. Stock is down 45% over the past year. The company is forecast to post earnings per share of ₹55.00 for next year compared to ₹41.72 last year.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 8 non-independent directors. Additional Independent Director Navin Shah was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Nov 09Second quarter 2023 earnings released: EPS: ₹7.72 (vs ₹9.42 in 2Q 2022)Second quarter 2023 results: EPS: ₹7.72 (down from ₹9.42 in 2Q 2022). Revenue: ₹2.66b (down 2.6% from 2Q 2022). Net income: ₹209.6m (down 18% from 2Q 2022). Profit margin: 7.9% (down from 9.4% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.Recent Insider Transactions • Sep 17Insider recently sold ₹4.3m worth of stockOn the 14th of September, Hemchand Gala sold around 5k shares on-market at roughly ₹855 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹158m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹819, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 31x in the Chemicals industry in India. Total loss to shareholders of 43% over the past year.Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹5.68 (vs ₹9.82 in 1Q 2022)First quarter 2023 results: EPS: ₹5.68 (down from ₹9.82 in 1Q 2022). Revenue: ₹2.68b (up 9.7% from 1Q 2022). Net income: ₹154.3m (down 42% from 1Q 2022). Profit margin: 5.8% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 15% growth forecast for the industry in India.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹616, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Chemicals industry in India. Total loss to shareholders of 58% over the past year.Recent Insider Transactions • Jul 04Head of Factory & Whole-Time Director recently bought ₹60k worth of stockOn the 29th of June, Vishnu Sawant bought around 100 shares on-market at roughly ₹596 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹60k. Despite this recent purchase, insiders have collectively sold ₹194m more in shares than they bought in the last 12 months.Recent Insider Transactions • Jun 25Insider recently sold ₹4.2m worth of stockOn the 20th of June, Hemchand Gala sold around 8k shares on-market at roughly ₹524 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹44m. Insiders have been net sellers, collectively disposing of ₹198m more than they bought in the last 12 months.Recent Insider Transactions • Jun 06Insider recently sold ₹3.1m worth of stockOn the 1st of June, Kenil Savla sold around 5k shares on-market at roughly ₹683 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹21m. Insiders have been net sellers, collectively disposing of ₹138m more than they bought in the last 12 months.Reported Earnings • May 29Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₹41.72 (down from ₹44.68 in FY 2021). Revenue: ₹11.5b (up 53% from FY 2021). Net income: ₹1.13b (down 1.1% from FY 2021). Profit margin: 9.8% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.4%. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 9.5%, compared to a 17% growth forecast for the industry in India.Price Target Changed • Apr 27Price target increased to ₹1,980Up from ₹1,782, the current price target is provided by 1 analyst. New target price is 123% above last closing price of ₹887. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₹50.80 for next year compared to ₹44.68 last year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Director Mulesh Savla was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Apr 06Be Wary Of Valiant Organics (NSE:VALIANTORG) And Its Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹1,010, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 27x in the Chemicals industry in India. Total loss to shareholders of 18% over the past year.Recent Insider Transactions • Feb 19Whole Time Director recently sold ₹5.7m worth of stockOn the 16th of February, Bijal Modi sold around 6k shares on-market at roughly ₹974 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹101m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹957, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 29% over the past year.Reported Earnings • Feb 08Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹11.02 (down from ₹12.56 in 3Q 2021). Revenue: ₹2.91b (up 41% from 3Q 2021). Net income: ₹299.4m (down 5.2% from 3Q 2021). Profit margin: 10% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 16%, compared to a 20% growth forecast for the industry in India.Recent Insider Transactions • Jan 02Insider recently sold ₹594k worth of stockOn the 31st of December, Maya Savla sold around 566 shares on-market at roughly ₹1,050 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹18m. Insiders have been net sellers, collectively disposing of ₹96m more than they bought in the last 12 months.Recent Insider Transactions • Nov 05Managing Director & Director recently sold ₹18m worth of stockOn the 2nd of November, Arvind Chheda sold around 14k shares on-market at roughly ₹1,316 per share. This was the largest sale by an insider in the last 3 months. This was Arvind's only on-market trade for the last 12 months.Reported Earnings • Nov 01Second quarter 2022 earnings released: EPS ₹9.42 (vs ₹12.64 in 2Q 2021)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹2.73b (up 64% from 2Q 2021). Net income: ₹255.9m (down 17% from 2Q 2021). Profit margin: 9.4% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹1,593, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 7.5% over the past year.Recent Insider Transactions • Sep 20Insider recently sold ₹1.3m worth of stockOn the 16th of September, Maya Savla sold around 908 shares on-market at roughly ₹1,467 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹16m. Insiders have been net sellers, collectively disposing of ₹51m more than they bought in the last 12 months.Executive Departure • Sep 10Company Secretary & Compliance Officer Vyoma Vyas has left the companyOn the 4th of September, Vyoma Vyas' tenure as Company Secretary & Compliance Officer ended after 4.3 years in the role. We don't have any record of a personal shareholding under Vyoma's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.42 years.Recent Insider Transactions • Sep 06Whole Time Director recently sold ₹16m worth of stockOn the 2nd of September, Bijal Modi sold around 12k shares on-market at roughly ₹1,296 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹43m more than they bought in the last 12 months.Executive Departure • Aug 21Non-Executive Director Dattatray Galpalli has left the companyOn the 14th of August, Dattatray Galpalli's tenure as Non-Executive Director ended after 4.1 years in the role. We don't have any record of a personal shareholding under Dattatray's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.33 years.Recent Insider Transactions • Aug 21Whole Time Director recently sold ₹3.0m worth of stockOn the 17th of August, Bijal Modi sold around 2k shares on-market at roughly ₹1,348 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹4.5m. Insiders have been net sellers, collectively disposing of ₹18m more than they bought in the last 12 months.Reported Earnings • Aug 19First quarter 2022 earnings released: EPS ₹9.82 (vs ₹11.40 in 1Q 2021)The company reported a mediocre first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: ₹2.46b (up 56% from 1Q 2021). Net income: ₹266.5m (down 3.8% from 1Q 2021). Profit margin: 11% (down from 18% in 1Q 2021). The decrease in margin was driven by higher expenses.Recent Insider Transactions • Jun 26Insider recently sold ₹4.5m worth of stockOn the 24th of June, Hemchand Gala sold around 3k shares on-market at roughly ₹1,496 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.Executive Departure • Jun 03Chief Financial Officer Piyush Lakhan has left the companyOn the 25th of May, Piyush Lakhan's tenure as Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Piyush's name. Piyush is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.17 years.Reported Earnings • May 28Full year 2021 earnings released: EPS ₹44.68 (vs ₹57.01 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: ₹7.61b (up 13% from FY 2020). Net income: ₹1.15b (down 17% from FY 2020). Profit margin: 15% (down from 21% in FY 2020). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • May 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,783, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 19x in the Chemicals industry in India.Recent Insider Transactions • Mar 23Whole Time Director recently sold ₹643k worth of stockOn the 18th of March, Bijal Modi sold around 510 shares on-market at roughly ₹1,261 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹8.0m more than they bought in the last 12 months.분석 기사 • Mar 03What To Know Before Buying Valiant Organics Limited (NSE:VALIANTORG) For Its DividendDividend paying stocks like Valiant Organics Limited ( NSE:VALIANTORG ) tend to be popular with investors, and for good...Is New 90 Day High Low • Feb 15New 90-day low: ₹1,339The company is down 14% from its price of ₹1,548 on 17 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.Reported Earnings • Feb 12Third quarter 2021 earnings released: EPS ₹12.56 (vs ₹12.18 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹2.07b (up 29% from 3Q 2020). Net income: ₹315.8m (up 6.7% from 3Q 2020). Profit margin: 15% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.주주 수익률VALIANTORGIN ChemicalsIN 시장7D-2.2%0.3%-0.7%1Y-39.2%-5.5%-4.3%전체 주주 수익률 보기수익률 대 산업: VALIANTORG은 지난 1년 동안 -5.5%의 수익을 기록한 Indian Chemicals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: VALIANTORG은 지난 1년 동안 -4.3%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is VALIANTORG's price volatile compared to industry and market?VALIANTORG volatilityVALIANTORG Average Weekly Movement11.4%Chemicals Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.7%안정적인 주가: VALIANTORG의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: VALIANTORG의 주간 변동성(11%)은 지난 1년 동안 안정적이었지만 Indian 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트1984942Sathiababu Kalladawww.valiantorganics.com화학물질 제조 회사인 발리언트 오가닉스는 인도에서 특수 화학물질을 제조 및 판매하는 회사입니다. 이 회사의 제품에는 파라 클로로 페놀, 오르토 클로로 페놀, 파라 플루로 아닐린, 4-플루로-N- 이소프로필 아닐린, 2,4-디클로로페녹시 아세트산, 2,4 디 클로로 페놀, 2,6 디 클로로 페놀, n- 이소프로필 파라 클로로 아닐린 및 2,4,6 트리 클로로 페놀 등이 있습니다; 오르토 아니시딘, 파라 아니시딘, 오르토 톨루이딘 5 설폰산, 오르토 니트로 아닐린 파라 설폰산, 오르토 아미노 페놀, 파라 니트로 아닐린, 오르토 클로로 파라 니트로 아닐린, IPPCA, 메타 클로로 아닐린 및 파라 아미노 페놀; 6 아세틸 오압사, OA 아세탄일아이드 및 PA 아세탄일아이드. 또한 오르토 클로로 파라 니트로 아닐린, OT5SA, 4b 및 2b 산, 오르토 니트로 아니솔, 파라 니트로 아니솔도 제공합니다.더 보기Valiant Organics Limited 기초 지표 요약Valiant Organics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?VALIANTORG 기초 통계시가총액₹7.99b순이익 (TTM)₹332.36m매출 (TTM)₹7.39b24.0x주가수익비율(P/E)1.1x주가매출비율(P/S)VALIANTORG는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표VALIANTORG 손익계산서 (TTM)매출₹7.39b매출원가₹4.37b총이익₹3.01b기타 비용₹2.68b순이익₹332.36m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)11.86총이익률40.80%순이익률4.50%부채/자본 비율33.3%VALIANTORG의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 05:21종가2026/06/09 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Valiant Organics Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nikhil ShettyBP Wealth Management Private Limited
분석 기사 • May 24Valiant Organics' (NSE:VALIANTORG) Solid Profits Have Weak FundamentalsValiant Organics Limited's ( NSE:VALIANTORG ) stock was strong after they recently reported robust earnings. We did...
공시 • May 20Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP.Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP on May 19, 2026. A cash consideration will be paid by Valiant Organics Limited. As part of consideration, Valiant Organics Limited declared that the acquisition price would not be higher by more than 25% of the price computed of INR 62.71 per equity share, based on the volume weighted average market price for a period of 60 trading days. The proposed acquisition is part of the restructuring exercise being undertaken by Valiant Organics Limited. Upon completion, Dhanvallabh Ventures LLP will retain 12.58% stake in Valiant Laboratories Limited. Subject to receipt of requisite approvals, the acquisition will be done any time after 4 working days from the date of this intimation.
Reported Earnings • May 17Full year 2026 earnings released: EPS: ₹11.86 (vs ₹1.35 loss in FY 2025)Full year 2026 results: EPS: ₹11.86 (up from ₹1.35 loss in FY 2025). Revenue: ₹7.46b (up 3.7% from FY 2025). Net income: ₹332.4m (up ₹369.7m from FY 2025). Profit margin: 4.5% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
공시 • May 12Valiant Organics Limited to Report Q4, 2026 Results on May 16, 2026Valiant Organics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 16, 2026
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹306, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 35% over the past three years.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹239, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 46% over the past three years.
분석 기사 • May 24Valiant Organics' (NSE:VALIANTORG) Solid Profits Have Weak FundamentalsValiant Organics Limited's ( NSE:VALIANTORG ) stock was strong after they recently reported robust earnings. We did...
공시 • May 20Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP.Valiant Organics Limited (BSE:540145) agreed to acquire 34.26% stake in Valiant Laboratories Limited (NSEI:VALIANTLAB) from Dhanvallabh Ventures LLP on May 19, 2026. A cash consideration will be paid by Valiant Organics Limited. As part of consideration, Valiant Organics Limited declared that the acquisition price would not be higher by more than 25% of the price computed of INR 62.71 per equity share, based on the volume weighted average market price for a period of 60 trading days. The proposed acquisition is part of the restructuring exercise being undertaken by Valiant Organics Limited. Upon completion, Dhanvallabh Ventures LLP will retain 12.58% stake in Valiant Laboratories Limited. Subject to receipt of requisite approvals, the acquisition will be done any time after 4 working days from the date of this intimation.
Reported Earnings • May 17Full year 2026 earnings released: EPS: ₹11.86 (vs ₹1.35 loss in FY 2025)Full year 2026 results: EPS: ₹11.86 (up from ₹1.35 loss in FY 2025). Revenue: ₹7.46b (up 3.7% from FY 2025). Net income: ₹332.4m (up ₹369.7m from FY 2025). Profit margin: 4.5% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
공시 • May 12Valiant Organics Limited to Report Q4, 2026 Results on May 16, 2026Valiant Organics Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 16, 2026
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹306, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 35% over the past three years.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹239, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 46% over the past three years.
Valuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹259, the stock trades at a trailing P/E ratio of 33.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 46% over the past three years.
New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₹6.66b market cap, or US$71.8m).
Reported Earnings • Feb 15Third quarter 2026 earnings released: EPS: ₹1.30 (vs ₹1.08 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.30. Revenue: ₹1.61b (down 14% from 3Q 2025). Net income: ₹36.5m (down 33% from 3Q 2025). Profit margin: 2.3% (down from 2.9% in 3Q 2025).
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹280, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 35% over the past three years.
공시 • Feb 09Valiant Organics Limited to Report Q3, 2026 Results on Feb 13, 2026Valiant Organics Limited announced that they will report Q3, 2026 results on Feb 13, 2026
분석 기사 • Feb 06Is Valiant Organics (NSE:VALIANTORG) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Nov 25Getting In Cheap On Valiant Organics Limited (NSE:VALIANTORG) Is UnlikelyThere wouldn't be many who think Valiant Organics Limited's ( NSE:VALIANTORG ) price-to-sales (or "P/S") ratio of 1x is...
Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹2.02 (vs ₹4.52 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.02 (up from ₹4.52 loss in 2Q 2025). Revenue: ₹1.58b (down 1.7% from 2Q 2025). Net income: ₹56.7m (up ₹184.5m from 2Q 2025). Profit margin: 3.6% (up from net loss in 2Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
공시 • Nov 10Valiant Organics Limited to Report Q2, 2026 Results on Nov 13, 2025Valiant Organics Limited announced that they will report Q2, 2026 results on Nov 13, 2025
New Risk • Oct 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.84b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.84b market cap, or US$99.6m).
공시 • Sep 01Valiant Organics Limited, Annual General Meeting, Sep 26, 2025Valiant Organics Limited, Annual General Meeting, Sep 26, 2025, at 11:30 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹2.93 (vs ₹0.23 loss in 1Q 2025)First quarter 2026 results: EPS: ₹2.93 (up from ₹0.23 loss in 1Q 2025). Revenue: ₹2.05b (up 22% from 1Q 2025). Net income: ₹82.0m (up ₹88.2m from 1Q 2025). Profit margin: 4.0% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
공시 • Aug 09Valiant Organics Limited to Report Q1, 2026 Results on Aug 13, 2025Valiant Organics Limited announced that they will report Q1, 2026 results on Aug 13, 2025
분석 기사 • Jul 30Be Wary Of Valiant Organics (NSE:VALIANTORG) And Its Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
분석 기사 • May 30Is Valiant Organics (NSE:VALIANTORG) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 23Full year 2025 earnings released: ₹1.24 loss per share (vs ₹3.08 loss in FY 2024)Full year 2025 results: ₹1.24 loss per share (improved from ₹3.08 loss in FY 2024). Revenue: ₹7.27b (flat on FY 2024). Net loss: ₹37.4m (loss narrowed 56% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
공시 • May 19Valiant Organics Limited to Report Q4, 2025 Results on May 22, 2025Valiant Organics Limited announced that they will report Q4, 2025 results on May 22, 2025
New Risk • May 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.33b (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.33b market cap, or US$97.3m).
분석 기사 • Apr 21Subdued Growth No Barrier To Valiant Organics Limited (NSE:VALIANTORG) With Shares Advancing 25%Valiant Organics Limited ( NSE:VALIANTORG ) shareholders would be excited to see that the share price has had a great...
Board Change • Apr 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Non-Executive Independent Director Sudhir Prakash Sawant was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공시 • Feb 07Valiant Organics Limited to Report Q3, 2025 Results on Feb 13, 2025Valiant Organics Limited announced that they will report Q3, 2025 results at 3:30 PM, Indian Standard Time on Feb 13, 2025
공시 • Jan 03+ 1 more updateValiant Organics Limited Approves the Appointment of Parimal H Desai as Managing DirectorValiant Organics Limited announced that Shri. Parimal H Desai appointed as Non- Executive Director effective from May 24, 2024 and subsequently as an Executive Director and Managing Director effective from January 01, 2025 as per the terms and conditions mentioned in the resolution approved by the shareholders through remote e-voting system. Reason for Change: Designated as Managing Director pursuant to section 196, 197, 203 read with Schedule V of the Companies Act, 2013. Shri. Parimal Desai holds a bachelor's degree in Chemical Engineering from UDCT, Mumbai. He is a proven technocrate with rich experience of nearly five decades in Chemical Industry, including Product Development, Project.
New Risk • Dec 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.40b (US$98.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 32% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.40b market cap, or US$98.2m).
Reported Earnings • Nov 15Second quarter 2025 earnings released: ₹4.52 loss per share (vs ₹1.58 profit in 2Q 2024)Second quarter 2025 results: ₹4.52 loss per share (down from ₹1.58 profit in 2Q 2024). Revenue: ₹1.63b (down 20% from 2Q 2024). Net loss: ₹127.8m (down 397% from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance.
공시 • Nov 09Valiant Organics Limited to Report Q2, 2025 Results on Nov 13, 2024Valiant Organics Limited announced that they will report Q2, 2025 results on Nov 13, 2024
공시 • Aug 07Valiant Organics Limited to Report Q1, 2025 Results on Aug 13, 2024Valiant Organics Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • Aug 01Full year 2024 earnings released: ₹3.08 loss per share (vs ₹32.45 profit in FY 2023)Full year 2024 results: ₹3.08 loss per share (down from ₹32.45 profit in FY 2023). Revenue: ₹7.23b (down 31% from FY 2023). Net loss: ₹83.9m (down 110% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 33% per year.
공시 • Jul 25Valiant Organics Limited, Annual General Meeting, Aug 21, 2024Valiant Organics Limited, Annual General Meeting, Aug 21, 2024, at 11:30 Indian Standard Time.
Reported Earnings • May 27Full year 2024 earnings released: ₹3.07 loss per share (vs ₹32.45 profit in FY 2023)Full year 2024 results: ₹3.07 loss per share (down from ₹32.45 profit in FY 2023). Revenue: ₹7.32b (down 30% from FY 2023). Net loss: ₹83.9m (down 110% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 36% per year.
공시 • May 25Valiant Organics Limited Announces Board Changes and Reconstitution of Committees of the BoardThe board of directors of Valiant Organics Limited at its meeting held on May 24, 2024, Appointment of Mr. Kaustubh Kulkarni (ACS: 52980) as the Company Secretary, Key Managerial Personnel and Compliance Officer of the Company with effect from May 24, 2024. Mr. Vishnu Sawant (DIN: 03477593) has tendered his resignation as an Executive Director of the Company with effect from close of business hours of May 31, 2024 citing pre-occupation and other personal commitments. Mr. Kaustubh Kulkarni (ACS 52980), is a member of the Institute of Company Secretaries of India and L.L.B. Graduate from Mumbai University. Mr. Kaustubh has over 7+ years of experience in dealing with Secretarial Compliances of Listed and Unlisted Companies across organizations engaged in the Pharmaceutical, Information Technology and Financial sector. Reconstitution of Committees of the Board: Corporate Social Responsibility Committee: Mr. Navin C. Shah: Independent Director, Chairperson; Mr. Mahek M. Chheda:Executive Director, Member; Mr. Nemin M. Savadia: Executive Director, Member. Risk Management Committee: Mr. Parimal H. Desai: Additional Non-Executive Director (Vice Chairman - Designated), Chairperson; Mr. Mulesh M. Savla: Independent Director, Member; Mr. Mahek M. Chheda: Executive Director, Member; Mr. Kallada K. Sathiababu: Executive Director, Member. Stakeholders Relationship Committee: Mr. Mulesh M. Savla: Independent Director, Chairperson; Mr. Navin C. Shah: Independent Director, Member; Mr. Mahek M. Chheda: Executive Director, Member.
Board Change • May 24Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Non-Executive Independent Director Sudhir Prakash Sawant was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공시 • May 18Valiant Organics Limited to Report Q4, 2024 Results on May 24, 2024Valiant Organics Limited announced that they will report Q4, 2024 results on May 24, 2024
New Risk • Feb 15New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 7.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin).
Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹2.90 loss per share (vs ₹8.09 profit in 3Q 2023)Third quarter 2024 results: ₹2.90 loss per share (down from ₹8.09 profit in 3Q 2023). Revenue: ₹1.42b (down 43% from 3Q 2023). Net loss: ₹78.9m (down 136% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
공시 • Feb 06Valiant Organics Limited to Report Q3, 2024 Results on Feb 13, 2024Valiant Organics Limited announced that they will report Q3, 2024 results on Feb 13, 2024
New Risk • Nov 13New major risk - Revenue and earnings growthEarnings have declined by 5.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹1.53 (vs ₹7.72 in 2Q 2023)Second quarter 2024 results: EPS: ₹1.53 (down from ₹7.72 in 2Q 2023). Revenue: ₹2.07b (down 22% from 2Q 2023). Net income: ₹43.0m (down 80% from 2Q 2023). Profit margin: 2.1% (down from 7.9% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
New Risk • Nov 09New major risk - Revenue and earnings growthEarnings have declined by 3.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
분석 기사 • Aug 31Estimating The Fair Value Of Valiant Organics Limited (NSE:VALIANTORG)Key Insights Valiant Organics' estimated fair value is ₹424 based on 2 Stage Free Cash Flow to Equity With ₹506 share...
공시 • Aug 24Valiant Organics Limited, Annual General Meeting, Sep 15, 2023Valiant Organics Limited, Annual General Meeting, Sep 15, 2023, at 11:00 Indian Standard Time. Agenda: To consider and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2023 together with the Reports of the Board of Directors' and the Auditors' thereon; to appoint a Director in place of Dr. Kiritkumar H. Desai; to appoint a Director in place of Shri Sathiababu K. Kallada; to discuss re-appoint the Statutory Auditors of the Company; to approve revision in terms & conditions of appointment of Shri Arvind K. Chheda Managing Director of the Company; and to discuss other matters.
Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: ₹4.58 (vs ₹5.68 in 1Q 2023)First quarter 2024 results: EPS: ₹4.58 (down from ₹5.68 in 1Q 2023). Revenue: ₹2.05b (down 23% from 1Q 2023). Net income: ₹124.2m (down 20% from 1Q 2023). Profit margin: 6.1% (up from 5.8% in 1Q 2023). The increase in margin was driven by lower expenses.
공시 • Aug 03Valiant Organics Limited to Report Q1, 2024 Results on Aug 09, 2023Valiant Organics Limited announced that they will report Q1, 2024 results on Aug 09, 2023
공시 • Jul 06Valiant Organics Limited Announces Cessation of Shri Velji Karamshi Gogri as an Independent Director Effective July 05, 2023Valiant Organics Limited announced that Shri Velji Karamshi Gogri (DIN: 02714758) completed his second consecutive term as an Independent Director on July 05, 2023 and consequently cease to be a Director of the Company with effect from closing of Business hours on July 05, 2023. The Board of Directors places on record appreciation for his contribution as an Independent Director with the Company.
Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹582, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 15% over the past year.
분석 기사 • May 24Valiant Organics (NSE:VALIANTORG) Will Be Hoping To Turn Its Returns On Capital AroundFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
공시 • May 21Valiant Organics Limited Announces Change in DirectorateValiant Organics Limited announced that Board of Directors at its Meeting held on May 19, 2023, have approved the appointment of Dr. Sudhirprakash B. Sawant (DIN: 02343218) as Additional Director in the Category of Non-Executive Independent Director the Company for a term of 5 (five) Years with effect from May 19, 2023 based on recommendation of Nomination and Remuneration Committee and subject to the approval of Members. Dr. Sudhirprakash B. Sawant holds a Bachelor's degree in Chemical Engineering and PhD. (Tech). He was a faculty member in Chemical Engineering. He has served as a consultant to various Chemical companies for more than 30 years. He has also served as an expert member on various committees of Central & State Governments.
Reported Earnings • May 21Full year 2023 earnings released: EPS: ₹32.45 (vs ₹41.72 in FY 2022)Full year 2023 results: EPS: ₹32.45 (down from ₹41.72 in FY 2022). Revenue: ₹10.6b (down 8.1% from FY 2022). Net income: ₹881.2m (down 22% from FY 2022). Profit margin: 8.3% (down from 9.8% in FY 2022). The decrease in margin was driven by lower revenue.
공시 • May 20Valiant Organics Limited Announces Reconstitution of Committees of the BoardValiant Organics Limited announced that at its board meeting held on May 19, 2023, approved reconstitution of Committees of the Board. Audit Committee: Shri Mulesh Savla - Independent Director, Chairman, Shri Arvind Chheda - Managing Director, Member, Shri Navin Shah - Independent Director, Member, Shri Sathiababu Kallada - Executive Director, Member, Smt. Sonal Vira - Independent Director, Member, Dr. Sudhirprakash B. Sawant - Independent Director, Member; Nomination and Remuneration Committee: Shri Mulesh Savla - Independent Director, Chairperson, Shri Santosh Shantilal Vora - Non-Executive Director, Member, Shri Navin Shah - Independent Director, Member; Risk Management Committee: Shri Mulesh Savla - Independent Director, Chairperson, Shri Mahek Manoj Chheda - Executive Director, Member, Shri Arvind Kanji Chheda - Managing Director, Member; Corporate Social Responsibility Committee: Shri Navin Shah - Independent Director, Chairperson, Shri Mahek Manoj Chheda - Executive Director, Member, Shri Arvind Kanji Chheda - Managing Director, Member.
공시 • May 13Valiant Organics Limited to Report Q4, 2023 Results on May 19, 2023Valiant Organics Limited announced that they will report Q4, 2023 results on May 19, 2023
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹505, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 46% over the past year.
Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹477, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 19x in the Chemicals industry in India. Total loss to shareholders of 52% over the past year.
Upcoming Dividend • Feb 03Upcoming dividend of ₹1.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 10 February 2023. Payment date: 02 March 2023. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).
공시 • Feb 01Valiant Organics Limited Declares Interim Dividend for the Financial Year 2022-2023Valiant Organics Limited announced that the board of directors of the company at its meeting held on January 31, 2023 has declared the interim dividend of INR 1 (10%) per equity share of INR 10 each for the financial year 2022-2023. Pursuant to Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, the board has fixed February 10, 2023, as record date for the purpose of payment of interim dividend.
Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹8.09 (vs ₹11.02 in 3Q 2022)Third quarter 2023 results: EPS: ₹8.09 (down from ₹11.02 in 3Q 2022). Revenue: ₹2.52b (down 13% from 3Q 2022). Net income: ₹219.7m (down 27% from 3Q 2022). Profit margin: 8.7% (down from 10% in 3Q 2022). The decrease in margin was driven by lower revenue.
공시 • Jan 24Valiant Organics Limited to Report Q3, 2023 Results on Jan 31, 2023Valiant Organics Limited announced that they will report Q3, 2023 results on Jan 31, 2023
Recent Insider Transactions • Dec 19Insider recently sold ₹2.9m worth of stockOn the 15th of December, Indira Dedhia sold around 5k shares on-market at roughly ₹637 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.9m. Insiders have been net sellers, collectively disposing of ₹119m more than they bought in the last 12 months.
Price Target Changed • Nov 16Price target decreased to ₹1,382Down from ₹1,980, the current price target is provided by 1 analyst. New target price is 110% above last closing price of ₹657. Stock is down 45% over the past year. The company is forecast to post earnings per share of ₹55.00 for next year compared to ₹41.72 last year.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 8 non-independent directors. Additional Independent Director Navin Shah was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Nov 09Second quarter 2023 earnings released: EPS: ₹7.72 (vs ₹9.42 in 2Q 2022)Second quarter 2023 results: EPS: ₹7.72 (down from ₹9.42 in 2Q 2022). Revenue: ₹2.66b (down 2.6% from 2Q 2022). Net income: ₹209.6m (down 18% from 2Q 2022). Profit margin: 7.9% (down from 9.4% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
Recent Insider Transactions • Sep 17Insider recently sold ₹4.3m worth of stockOn the 14th of September, Hemchand Gala sold around 5k shares on-market at roughly ₹855 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹158m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹819, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 31x in the Chemicals industry in India. Total loss to shareholders of 43% over the past year.
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹5.68 (vs ₹9.82 in 1Q 2022)First quarter 2023 results: EPS: ₹5.68 (down from ₹9.82 in 1Q 2022). Revenue: ₹2.68b (up 9.7% from 1Q 2022). Net income: ₹154.3m (down 42% from 1Q 2022). Profit margin: 5.8% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 15% growth forecast for the industry in India.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹616, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Chemicals industry in India. Total loss to shareholders of 58% over the past year.
Recent Insider Transactions • Jul 04Head of Factory & Whole-Time Director recently bought ₹60k worth of stockOn the 29th of June, Vishnu Sawant bought around 100 shares on-market at roughly ₹596 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹60k. Despite this recent purchase, insiders have collectively sold ₹194m more in shares than they bought in the last 12 months.
Recent Insider Transactions • Jun 25Insider recently sold ₹4.2m worth of stockOn the 20th of June, Hemchand Gala sold around 8k shares on-market at roughly ₹524 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹44m. Insiders have been net sellers, collectively disposing of ₹198m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 06Insider recently sold ₹3.1m worth of stockOn the 1st of June, Kenil Savla sold around 5k shares on-market at roughly ₹683 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹21m. Insiders have been net sellers, collectively disposing of ₹138m more than they bought in the last 12 months.
Reported Earnings • May 29Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₹41.72 (down from ₹44.68 in FY 2021). Revenue: ₹11.5b (up 53% from FY 2021). Net income: ₹1.13b (down 1.1% from FY 2021). Profit margin: 9.8% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.4%. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 9.5%, compared to a 17% growth forecast for the industry in India.
Price Target Changed • Apr 27Price target increased to ₹1,980Up from ₹1,782, the current price target is provided by 1 analyst. New target price is 123% above last closing price of ₹887. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₹50.80 for next year compared to ₹44.68 last year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Director Mulesh Savla was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Apr 06Be Wary Of Valiant Organics (NSE:VALIANTORG) And Its Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹1,010, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 27x in the Chemicals industry in India. Total loss to shareholders of 18% over the past year.
Recent Insider Transactions • Feb 19Whole Time Director recently sold ₹5.7m worth of stockOn the 16th of February, Bijal Modi sold around 6k shares on-market at roughly ₹974 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹101m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹957, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 29% over the past year.
Reported Earnings • Feb 08Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹11.02 (down from ₹12.56 in 3Q 2021). Revenue: ₹2.91b (up 41% from 3Q 2021). Net income: ₹299.4m (down 5.2% from 3Q 2021). Profit margin: 10% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 16%, compared to a 20% growth forecast for the industry in India.
Recent Insider Transactions • Jan 02Insider recently sold ₹594k worth of stockOn the 31st of December, Maya Savla sold around 566 shares on-market at roughly ₹1,050 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹18m. Insiders have been net sellers, collectively disposing of ₹96m more than they bought in the last 12 months.
Recent Insider Transactions • Nov 05Managing Director & Director recently sold ₹18m worth of stockOn the 2nd of November, Arvind Chheda sold around 14k shares on-market at roughly ₹1,316 per share. This was the largest sale by an insider in the last 3 months. This was Arvind's only on-market trade for the last 12 months.
Reported Earnings • Nov 01Second quarter 2022 earnings released: EPS ₹9.42 (vs ₹12.64 in 2Q 2021)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹2.73b (up 64% from 2Q 2021). Net income: ₹255.9m (down 17% from 2Q 2021). Profit margin: 9.4% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹1,593, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 7.5% over the past year.
Recent Insider Transactions • Sep 20Insider recently sold ₹1.3m worth of stockOn the 16th of September, Maya Savla sold around 908 shares on-market at roughly ₹1,467 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹16m. Insiders have been net sellers, collectively disposing of ₹51m more than they bought in the last 12 months.
Executive Departure • Sep 10Company Secretary & Compliance Officer Vyoma Vyas has left the companyOn the 4th of September, Vyoma Vyas' tenure as Company Secretary & Compliance Officer ended after 4.3 years in the role. We don't have any record of a personal shareholding under Vyoma's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.42 years.
Recent Insider Transactions • Sep 06Whole Time Director recently sold ₹16m worth of stockOn the 2nd of September, Bijal Modi sold around 12k shares on-market at roughly ₹1,296 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹43m more than they bought in the last 12 months.
Executive Departure • Aug 21Non-Executive Director Dattatray Galpalli has left the companyOn the 14th of August, Dattatray Galpalli's tenure as Non-Executive Director ended after 4.1 years in the role. We don't have any record of a personal shareholding under Dattatray's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.33 years.
Recent Insider Transactions • Aug 21Whole Time Director recently sold ₹3.0m worth of stockOn the 17th of August, Bijal Modi sold around 2k shares on-market at roughly ₹1,348 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹4.5m. Insiders have been net sellers, collectively disposing of ₹18m more than they bought in the last 12 months.
Reported Earnings • Aug 19First quarter 2022 earnings released: EPS ₹9.82 (vs ₹11.40 in 1Q 2021)The company reported a mediocre first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: ₹2.46b (up 56% from 1Q 2021). Net income: ₹266.5m (down 3.8% from 1Q 2021). Profit margin: 11% (down from 18% in 1Q 2021). The decrease in margin was driven by higher expenses.
Recent Insider Transactions • Jun 26Insider recently sold ₹4.5m worth of stockOn the 24th of June, Hemchand Gala sold around 3k shares on-market at roughly ₹1,496 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.
Executive Departure • Jun 03Chief Financial Officer Piyush Lakhan has left the companyOn the 25th of May, Piyush Lakhan's tenure as Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Piyush's name. Piyush is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.17 years.
Reported Earnings • May 28Full year 2021 earnings released: EPS ₹44.68 (vs ₹57.01 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: ₹7.61b (up 13% from FY 2020). Net income: ₹1.15b (down 17% from FY 2020). Profit margin: 15% (down from 21% in FY 2020). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,783, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 19x in the Chemicals industry in India.
Recent Insider Transactions • Mar 23Whole Time Director recently sold ₹643k worth of stockOn the 18th of March, Bijal Modi sold around 510 shares on-market at roughly ₹1,261 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹8.0m more than they bought in the last 12 months.
분석 기사 • Mar 03What To Know Before Buying Valiant Organics Limited (NSE:VALIANTORG) For Its DividendDividend paying stocks like Valiant Organics Limited ( NSE:VALIANTORG ) tend to be popular with investors, and for good...
Is New 90 Day High Low • Feb 15New 90-day low: ₹1,339The company is down 14% from its price of ₹1,548 on 17 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
Reported Earnings • Feb 12Third quarter 2021 earnings released: EPS ₹12.56 (vs ₹12.18 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹2.07b (up 29% from 3Q 2020). Net income: ₹315.8m (up 6.7% from 3Q 2020). Profit margin: 15% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.
